Table 3: Receipt of care among persons aged ≥13 years living with HIV, 17 US jurisdictionsa, 2012-2015.
| Characteristic |
Receipt of Careb |
| 2012 |
2013 |
2014 |
2015 |
Trend in 2012-2015 |
| (N=440,375) |
(N=451,885) |
(N=464,461) |
(N=477,928) |
EAPC |
95% CI |
P-value |
| No. |
(%) |
No. |
(%) |
No. |
(%) |
No. |
(%) |
Lower |
Upper |
| Sex |
|
|
|
|
|
|
|
|
|
|
|
|
| Male |
240,338 |
70.8 |
250,253 |
71.6 |
261,047 |
72.5 |
267,644 |
72.1 |
0.7 |
0.5 |
0.8 |
<.001 |
| Female |
72,100 |
71.5 |
73,956 |
72.2 |
75,582 |
72.4 |
77,191 |
72.4 |
0.4 |
0.1 |
0.7 |
.011 |
| Race/Ethnicity |
|
|
|
|
|
|
|
|
|
|
|
|
| Black/African American |
117,215 |
68.2 |
122,090 |
69.4 |
126,963 |
69.9 |
130,784 |
69.8 |
0.8 |
0.5 |
1.1 |
<.001 |
| Hispanic/Latino |
75,236 |
68.9 |
78,513 |
69.3 |
82,354 |
70.2 |
85,046 |
69.8 |
0.5 |
0.2 |
0.8 |
<.001 |
| White |
98,207 |
74.7 |
101,076 |
75.3 |
103,959 |
76.4 |
105,162 |
75.7 |
0.5 |
0.3 |
0.8 |
<.001 |
| Other |
21,780 |
78.8 |
22,530 |
79.4 |
23,353 |
79.7 |
23,843 |
79.4 |
0.3 |
-0.3 |
0.8 |
.379 |
| Age group at diagnosis |
|
|
|
|
|
|
|
|
|
|
|
|
| 13-24 |
10,941 |
70.2 |
11,546 |
72.5 |
11,819 |
74.5 |
11,753 |
75.2 |
2.4 |
1.5 |
3.2 |
<.001 |
| 25-34 |
42,941 |
68.9 |
45,144 |
70.4 |
48,086 |
71.8 |
50,639 |
72.5 |
1.7 |
1.3 |
2.1 |
<.001 |
| 35-44 |
76,771 |
70.2 |
74,827 |
71.0 |
73,406 |
71.6 |
71,621 |
71.4 |
0.6 |
0.3 |
0.9 |
<.001 |
| 45-54 |
114,184 |
72.7 |
116,821 |
73.3 |
118,737 |
73.8 |
118,052 |
73.2 |
0.2 |
0 |
0.5 |
.058 |
| 55+ |
67,601 |
70.3 |
75,871 |
70.8 |
84,581 |
71.5 |
92,770 |
71.0 |
0.3 |
0 |
0.6 |
.039 |
| Stage at diagnosis |
|
|
|
|
|
|
|
|
|
|
|
|
| HIV infection stage 3(AIDS) |
77,369 |
70.8 |
79,592 |
71.5 |
81,523 |
72.0 |
82,732 |
71.7 |
0.4 |
0.1 |
0.7 |
.006 |
| Not known to be HIV infection stage 3 |
235,069 |
71.0 |
244,617 |
71.8 |
255,106 |
72.6 |
262,103 |
72.3 |
0.6 |
0.5 |
0.8 |
<.001 |
| Transmission Categoryc |
|
|
|
|
|
|
|
|
|
|
|
|
| Male-to-male sexual contact |
172,781 |
72.7 |
181,665 |
73.4 |
191,919 |
74.4 |
198,957 |
73.9 |
0.6 |
0.4 |
0.8 |
<.001 |
| Injection drug use |
44,880 |
63.9 |
44,843 |
64.6 |
44,350 |
64.6 |
43,421 |
63.9 |
0 |
-0.4 |
0.4 |
.926 |
| Male-to-male sexual contact and injection drug use |
21,469 |
75.3 |
21,684 |
76.5 |
21,828 |
77.2 |
21,607 |
76.6 |
0.6 |
0 |
1.2 |
.037 |
| Heterosexual contactd
|
72,026 |
70.6 |
74,735 |
71.4 |
77,251 |
71.7 |
79,574 |
71.8 |
0.5 |
0.2 |
0.8 |
.001 |
| Othere
|
1,282 |
68.8 |
1,283 |
69.4 |
1,281 |
69.8 |
1,276 |
69.0 |
0.1 |
-2.3 |
2.6 |
.912 |
| Total |
312,438 |
70.9 |
324,209 |
71.7 |
336,629 |
72.5 |
344,835 |
72.2 |
0.6 |
0.4 |
0.8 |
<.001 |
Abbreviations: HIV= Human Immunodeficiency Virus, EAPC=Estimated Annual Percent Change.
Note: The denominator for each characteristic for each year are not presented.
aJurisdictions include California, District of Columbia, Hawaii, Iowa, Illinois, Indiana, Louisiana, Maryland, Michigan, Missouri, New Hampshire, New York, North Dakota, South Carolina, Texas, Utah, and West Virginia.
bDefined as one or more CD4+ T-lymphocyte or viral load test performed during the outcome year.
cData statistically adjusted to account for missing transmission categories.
dHeterosexual contact with a person known to have, or to be at high risk for, HIV infection.
eIncludes hemophilia, blood transfusion, perinatal exposure and risk factor not reported or not identified.